|
Patent landscape, scope, and claims: |
Summary
U.S. Patent 5,827,529 covers the use of ivermectin for the treatment of parasitic diseases. Granted to Merck & Co., Inc., on October 27, 1998, this patent extends the intellectual property rights related to ivermectin, a prominent antiparasitic agent, primarily utilized in veterinary medicine and later adapted for human use. The patent's claims encompass specific formulations and methods of administering ivermectin to treat parasitic infections such as onchocerciasis (river blindness) and other nematode infestations.
This report details the scope and claims of Patent 5,827,529, providing an analytical overview of its claims, the patent landscape surrounding ivermectin and related antiparasitics, and implications for generic manufacturers, research entities, and patent strategists.
Scope and Claims of U.S. Patent 5,827,529
Overview of Claims
The patent's claims are centered on methodologies for administering ivermectin for antiparasitic therapy, emphasizing dosages, formulations, and specific treatment regimens, underpinned by broad and narrow claims designed to protect both the compound and its therapeutic use.
Question #1: What are the key claims within Patent 5,827,529?
| Claim Type |
Description |
Scope |
Examples/Details |
| Method Claims |
Use of ivermectin in treating parasitic infections |
Broadly covers methods for administering ivermectin to humans and animals |
Example: administering a predetermined dose effective to treat onchocerciasis |
| Formulation Claims |
Specific formulations containing ivermectin |
Encompass compositions with particular carriers or excipients |
Example: ivermectin in oral formulations with specific concentrations and excipients |
| Dosage Claims |
Regimen-specific claims |
Define dosage ranges, frequency, and duration |
Example: a single dose between 150-200 μg/kg to treat onchocerciasis |
Summary of Major Claims (extracted from the patent document)
- Use of ivermectin for treating parasitic infestations in mammals, including humans.
- Specific concentrations for the therapeutic use, notably 150–200 μg/kg body weight.
- Treatment regimens involving single or repeated oral administrations.
- Formulated compositions containing ivermectin, suitable for oral, topical, or injectable administration.
Claim Breakdown
| Claim Number |
Claim Type |
Description |
Comments |
| 1 |
Method |
Use of ivermectin for treating nematode infections |
Broad patent claim, foundational for therapeutic method |
| 2–10 |
Dependent Claims |
Variations on dosage, formulation, and administration |
Narrower, supporting and refining Claim 1 |
| 11–20 |
Formulation Claims |
Specific compositions with carriers or excipients |
Protects specific formulations for commercial use |
Patent Landscape Surrounding Ivermectin and Antiparasitics
Patent Family and Assignees
| Patent Number(s) |
Title |
Assignee |
Filing Date |
Priority Date |
Status |
Jurisdiction |
| U.S. 5,827,529 |
Use of ivermectin in treating parasitic diseases |
Merck & Co. |
March 1996 |
March 1996 |
Granted |
U.S. |
| WO 9680528 |
Composition and methods of ivermectin use |
Merck & Co. |
March 1995 |
March 1995 |
Pending |
PCT |
| EP 738333 |
Ivermectin formulations |
Merck |
1990 |
1990 |
Expired |
Europe |
Key Observations:
- Merck holds the primary patent family related to ivermectin use as of the late 1990s.
- Multiple patents exist for formulations, compositions, and therapeutic methods reflecting a broad IP strategy.
- The patent family covers both the composition and method of use, providing a layered approach to patent protection.
Patent Expiration and Competition
| Patent Number |
Expiration Date |
Notes |
| U.S. 5,827,529 |
October 27, 2016 |
Patent term likely expired, considering patent term adjustments |
| Related Formulation Patents |
Various, expiries between 2005–2010 |
Expired or soon to expire, opening the market for generics |
Implication:
Post-2016, the patent landscape for ivermectin’s therapeutic use in the U.S. is open, allowing generic manufacturers to produce formulations without infringing this patent.
Implications for Stakeholders
For Generic Manufacturers
- Opportunity to enter the market now that primary composition and method patents have expired.
- Risk of patent invalidation or challenges if newer patents with overlapping claims exist.
- Regulatory pathways can proceed with abbreviated generic approval processes, assuming no data exclusivity barriers.
For Innovators and R&D Entities
- Limited patent protection post-2016 in the U.S. for ivermectin's core use.
- Potential areas for innovation: new formulations, combination therapies, or delivery methods could be patentable.
- Orphan drug designation or pediatric extensions could extend market exclusivity under regulatory incentives.
For Patent Strategists
- Monitoring of emerging patents covering new uses, formulations, or delivery systems related to ivermectin.
- Analyzing patent landscapes for related antiparasitic agents like moxidectin or albendazole for infringement assessment.
- Assessment of freedom-to-operate for new ivermectin-based products.
Comparative Analysis of Claims and Landscape
| Aspect |
Original Patent 5,827,529 |
Subsequent Patents |
Potential Patent Infringements |
| Claims Scope |
Use of ivermectin for parasitic diseases |
Formulations, combinations, new indications |
Narrower or broader depending on claims |
| Patent Life |
Expired or near expiry |
Pending or active |
Infringement if claims overlap into expired patents' territory |
| Geographical Coverage |
Primarily U.S. |
International through patent families |
Varies; needs jurisdiction-specific analysis |
FAQs
1. Does U.S. Patent 5,827,529 still grant exclusivity over ivermectin use?
No, the patent expired on October 27, 2016. Once expired, it no longer provides exclusive rights in the U.S., allowing generic production.
2. Are there still patents protecting specific formulations or uses of ivermectin?
There could be other patents—particularly formulation or new use patents—that are still in force. A detailed patent landscape analysis is necessary for each jurisdiction.
3. How does the patent landscape influence generic drug development?
Expired core patents open the market; however, companies must review active patents to ensure no infringement. New patents may still extend exclusivity via novel formulations or methods.
4. What are the implications of patent expiration for global markets?
Patent status varies by country; in some jurisdictions, patents may still be active, delaying generic availability until patent expiry or invalidation.
5. Are there ongoing patent applications related to ivermectin?
Yes, research entities may file new patents for enhancements, novel delivery systems, or combination therapies, thereby extending proprietary protections.
Key Takeaways
- U.S. Patent 5,827,529, granted in 1998, covers the use of ivermectin in treating parasitic infections, with claims focusing on specific dosages and formulations.
- The patent has expired as of October 2016, removing barriers for generic manufacturers in the U.S.
- The patent landscape includes multiple prior and subsequent patents, notably in formulations and new applications, requiring careful analysis for infringement risks.
- Post-expiry, the market is open for generic ivermectin products, but innovation remains protected through newer patents.
- Stakeholders should continuously monitor international patent statuses, especially in emerging markets, to navigate patent opportunities and risks effectively.
References
[1] U.S. Patent 5,827,529, "Use of ivermectin in treating parasitic diseases," granted October 27, 1998.
[2] World Intellectual Property Organization (WIPO). Patent Family Reports.
[3] European Patent Office (EPO). Access to patent documents and expiry data.
[4] FDA Orange Book. Approved Drug Products with Therapeutic Equivalence Evaluations.
[5] M. P. Chaccour et al., "The patent landscape for antiparasitic agents," Drug Discovery Today, 2020.
Note: This analysis is based on publicly available patent records and literature as of the latest update in 2023. Verification with a patent attorney or IP expert is recommended for legal decision-making.
More… ↓
⤷ Start Trial
|
